Japan Diabetes Market Report 2019-2024 | Industry Trends, Market Share, Size, Growth and Opportunities
The latest report by IMARC Group, “Japan Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics”, finds that the market is further expected to reach a value of US$ 5 Million by 2024.
Japan had more than seven million people diagnosed with diabetes. The major cause of diabetes in Japan is unhealthy dietary habits which has resulted in 65% growth in diabetes cases in the region. The Japanese culinary tradition is centred on foods which trigger obesity, such as excessive intake of white rice, noodles, high sugar food, pickled vegetables, spices, etc. However, in order to curtail obesity and prevent the dissemination of diabetes, the Japanese government launched anti-obesity campaign in 2008. It mandates limiting waistline for adults between the ages 40 and 75 within accepted standards. Apart from this, aging-population and low-birth-rates, and sedentary lifestyle have emerged as important factors for the cause of diabetes in the region.
Request to get the sample report: https://www.imarcgroup.com/japan-diabetes-market/requestsample
Highlights of the Japan Diabetes market:
Government intervention is the biggest driving force for the growth of the market.
Insulin represents the largest market, accounting for the majority of the share.
The market is expected to reach a value of US$ 5 Billion by 2024.
The Japanese government provides universal health coverage to its citizens, under which treatment costs are covered by national health insurance. Apart from this, Japan also has one of the highest per capita spending on drugs and most people can afford expensive treatments for diseases, such as diabetes. As a result of this, the demand for medicines and equipment for the treatment of diabetes is increasing in Japan. This offers enough opportunities to the manufacturers in the pharmaceuticals industry to create a market for their products in the region. The market is further expected to reach a value of US$ 5 Million by 2024.
The market is bifurcated as oral antidiabetics and insulin. Insulin represents the largest market, accounting for the majority of the share. An analysis of the competitive landscape provides the details of the key players operative in the market. Some of the major player are Sanofi K.K., Novo-Nordisk, Takeda, Eli Lily Japan K.K., and Ono. The report provides an analytical and statistical insight into the Japanese diabetes market. It also offers both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in Japan.
Browse full report with detailed TOC and list of figures and tables: https://www.imarcgroup.com/japan-diabetes-market
The report examines the Japan diabetes market on the basis of:
Segment:
- Oral Antidiabetics
- Insulin
Key Players:
- Sanofi K.K
- Novo-Nordisk
- Takeda
- Eli Lily Japan K.K.
- Ono
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
30 N Gould St
Ste R
Sheridan, WY 82801
USA
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
